San Diego-primarily based Viking Therapeutics marked alone as a serious competitor from the weight loss drug current market in February right after revealing promising facts from the mid-phase trial of experimental drug VK2735, which proposed it rivaled—and outperformed—Novo and Lilly drugs when specified as being a weekly injection and in Marc